LLY Quote, Financials, Valuation and Earnings

Biogen, Inc. has a net margin of 31.72% compared to Eli Lilly & Co.'s net margin of 19%. Eli Lilly & Co.'s return on equity of 106.26% beat Biogen, Inc.'s return on equity of 9.36%.

Eli Lilly & Co. has a consensus price target of $1,133.93, signalling upside risk potential of 9.33%. On the other hand Biogen, Inc. has an analysts' consensus of $193.00 which suggests that it could grow by 7.29%. Given that Eli Lilly & Co. has higher upside potential than Biogen, Inc., analysts believe Eli Lilly & Co. is more attractive than Biogen, Inc..

Eli Lilly & Co. has a beta of 0.348, which suggesting that the stock is 65.185% less volatile than S&P 500. In comparison Biogen, Inc. has a beta of 0.127, suggesting its less volatile than the S&P 500 by 87.301%.

Eli Lilly & Co. has a quarterly dividend of $1.50 per share corresponding to a yield of 0.58%. Biogen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eli Lilly & Co. pays 44.39% of its earnings as a dividend. Biogen, Inc. pays out -- of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Eli Lilly & Co. quarterly revenues are $17.6B, which are larger than Biogen, Inc. quarterly revenues of $2.5B. Eli Lilly & Co.'s net income of $5.6B is higher than Biogen, Inc.'s net income of $466.5M. Notably, Eli Lilly & Co.'s price-to-earnings ratio is 51.29x while Biogen, Inc.'s PE ratio is 16.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eli Lilly & Co. is 15.91x versus 2.72x for Biogen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Moderna, Inc. has a net margin of 31.72% compared to Eli Lilly & Co.'s net margin of -19.69%. Eli Lilly & Co.'s return on equity of 106.26% beat Moderna, Inc.'s return on equity of -30.18%.

Eli Lilly & Co. has a consensus price target of $1,133.93, signalling upside risk potential of 9.33%. On the other hand Moderna, Inc. has an analysts' consensus of $37.65 which suggests that it could fall by -14.57%. Given that Eli Lilly & Co. has higher upside potential than Moderna, Inc., analysts believe Eli Lilly & Co. is more attractive than Moderna, Inc..

Eli Lilly & Co. has a beta of 0.348, which suggesting that the stock is 65.185% less volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.170, suggesting its more volatile than the S&P 500 by 16.991%.

Eli Lilly & Co. has a quarterly dividend of $1.50 per share corresponding to a yield of 0.58%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eli Lilly & Co. pays 44.39% of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Eli Lilly & Co. quarterly revenues are $17.6B, which are larger than Moderna, Inc. quarterly revenues of $1B. Eli Lilly & Co.'s net income of $5.6B is higher than Moderna, Inc.'s net income of -$200M. Notably, Eli Lilly & Co.'s price-to-earnings ratio is 51.29x while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eli Lilly & Co. is 15.91x versus 7.65x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of 31.72% compared to Eli Lilly & Co.'s net margin of 21.74%. Eli Lilly & Co.'s return on equity of 106.26% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 14.93%.

Eli Lilly & Co. has a consensus price target of $1,133.93, signalling upside risk potential of 9.33%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $842.42 which suggests that it could grow by 12.75%. Given that Regeneron Pharmaceuticals, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Regeneron Pharmaceuticals, Inc. is more attractive than Eli Lilly & Co..

Eli Lilly & Co. has a beta of 0.348, which suggesting that the stock is 65.185% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.390, suggesting its less volatile than the S&P 500 by 60.965%.

Eli Lilly & Co. has a quarterly dividend of $1.50 per share corresponding to a yield of 0.58%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.48% to investors and pays a quarterly dividend of $0.88 per share. Eli Lilly & Co. pays 44.39% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out 8.49% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Eli Lilly & Co. quarterly revenues are $17.6B, which are larger than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.9B. Eli Lilly & Co.'s net income of $5.6B is higher than Regeneron Pharmaceuticals, Inc.'s net income of $844.6M. Notably, Eli Lilly & Co.'s price-to-earnings ratio is 51.29x while Regeneron Pharmaceuticals, Inc.'s PE ratio is 17.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eli Lilly & Co. is 15.91x versus 5.62x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics, Inc. has a net margin of 31.72% compared to Eli Lilly & Co.'s net margin of --. Eli Lilly & Co.'s return on equity of 106.26% beat Viking Therapeutics, Inc.'s return on equity of -28.62%.

Eli Lilly & Co. has a consensus price target of $1,133.93, signalling upside risk potential of 9.33%. On the other hand Viking Therapeutics, Inc. has an analysts' consensus of $93.39 which suggests that it could grow by 221.59%. Given that Viking Therapeutics, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Viking Therapeutics, Inc. is more attractive than Eli Lilly & Co..

Eli Lilly & Co. has a beta of 0.348, which suggesting that the stock is 65.185% less volatile than S&P 500. In comparison Viking Therapeutics, Inc. has a beta of 0.710, suggesting its less volatile than the S&P 500 by 28.988%.

Eli Lilly & Co. has a quarterly dividend of $1.50 per share corresponding to a yield of 0.58%. Viking Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eli Lilly & Co. pays 44.39% of its earnings as a dividend. Viking Therapeutics, Inc. pays out -- of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Eli Lilly & Co. quarterly revenues are $17.6B, which are larger than Viking Therapeutics, Inc. quarterly revenues of --. Eli Lilly & Co.'s net income of $5.6B is higher than Viking Therapeutics, Inc.'s net income of -$90.8M. Notably, Eli Lilly & Co.'s price-to-earnings ratio is 51.29x while Viking Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eli Lilly & Co. is 15.91x versus -- for Viking Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.